Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

March 30, 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

April 07, 2024

UK Mini Mitral: No Clear Win for Minimally Invasive MV Repair

News Conference News ACC 2023

UK Mini Mitral: No Clear Win for Minimally Invasive MV Repair

March 13, 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

March 05, 2023

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

News Conference News ACC 2020

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

Michael O'Riordan

March 29, 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

News Conference News ACC 2020

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

March 29, 2020

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

March 11, 2019

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

March 19, 2018

NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients

News Conference News ACC 2018

NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients

March 10, 2018

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

News Conference News ACC 2016

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

April 04, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

April 02, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.